Norethindrone/Ethinyl Estradiol 0.4 mg/35 Mcg Chewable Tablets Under Non-Fasted Conditions

Teva Pharmaceuticals

Status and phase

Completed

Phase 1

Conditions

Healthy

Treatments

Drug: FEMCON® Fe

Drug: Norethindrone/Ethinyl Estradiol

Study type

Interventional

Funder types

Industry

Identifiers

NCT01344369

10816221

Details and patient eligibility

About

The purpose of this study was to evaluate the relative bioavailability of a test formulation of norethindrone/ethinyl estradiol 0.4 mg/0.035 mg chewable tablets (Teva Pharmaceuticals, USA) compared to the reference listed product, FEMCON® Fe (norethindrone/ethinyl estradiol and ferrous fumarate) 0.4 mg/0.035 mg Chewable tablets (Warner Chilcott) under fed conditions in healthy, non-tobacco using, adult female subjects.

Enrollment

36 patients

Sex

Female

Ages

18 to 45 years old

Volunteers

Accepts Healthy Volunteers

Inclusion criteria

Females, 18-45 years of age inclusive with Body Mass Index within 18-30 kg/m2 inclusive, as described in Novum Standard Operating Procedures. Female subjects must either abstain from sexual intercourse or use a reliable non-hormonal method of contraception (e.g. condom with spermicide, diaphragm, non-hormonal IUD) from at least 14 days prior to the first study dosing, throughout the study, and until 14 days after the last dose.
Normal menstrual cycle.
Good health as determined by lack of clinically significant abnormalities in health assessments performed at screening.
Signed and dated informed consent form, which meets all criteria of current FDA regulations.

Exclusion criteria

Post menopausal or have irregular menstrual cycle.
Pregnant, lactating, or likely to become pregnant during the study.
History of any drug hypersensitivity or intolerance which, in the opinion of the Investigator, would compromise the safety of the subject or the study.
Significant history or current evidence of chronic infectious disease, system disorder, or organ dysfunction.
Presence of gastrointestinal disease or history of malabsorption within the last year.
History of psychiatric disorders occurring within the last two years that required hospitalization or medication.
Presence of a medical condition requiring regular treatment with prescription drugs.
Use of pharmacologic agents known to significantly induce or inhibit drug-metabolizing enzymes within 30 days prior to dosing.
Participation in any clinical trial within 30 days prior to dosing.
Drug or alcohol addiction requiring treatment in the past 12 months.
Donation or significant loss of whole blood (480 mL or more) within 30 days or plasma within 14 days prior to dosing.
Positive test results for HIV, Hepatitis B surface antigen, or Hepatitis C antibody.
Positive test results for drugs of abuse at screening.
Positive serum pregnancy test.
Subjects who have ever had progestational hormone implants.
Subjects who have had progestational hormone depot injections within 12 months proceeding dosing.
Subjects who are using or have used within the 3 months preceding dosing any vaginally administered estrogen or progestin-containing products.
Any personal or strong family history of estrogen- or progestogen-dependent tumors.
History of clinically significant fibrocystic breast disease.
Subjects with a history of thromboembolic disorders, myocardial infarction, or stroke.
Use of norethindrone or ethinyl estrodiol-containing oral contraceptives within 30 days of initial dosing.
Hysterectomy or oophorectomy (unilateral or bilateral)
User of tobacco or nicotine containing products within 30 days of the start of the study.